Amneal Pharmaceuticals, Inc. (AMRX) Stock Price & How to Invest

Amneal Pharmaceuticals is a Bridgewater, New Jersey based biopharmaceutical company with a portfolio of roughly 300 complex generic, specialty, and biosimilar medicines that fill more than 160 million prescriptions a year, mostly in the United States. The business runs in three segments: Affordable Medicines (retail generics, injectables, and biosimilars, the largest at roughly 58% of revenue), Specialty (branded neurology and endocrinology treatments including Parkinson's disease and migraine, around 17% of revenue), and AvKARE (distribution to US federal, retail, and institutional customers, roughly 25% of revenue).

The investment picture centers on a mix shift. Traditional generics face relentless pricing pressure and thin margins, so Amneal is leaning into complex injectables, specialty branded drugs, and biosimilars, which carry higher margins but also higher development costs and manufacturing complexity. Recent results show that shift gaining traction, with Specialty growing fast and adjusted EBITDA rising, but the company also carries a sizable debt load and is spending to expand its biosimilars platform, including the pending Kashiv BioSciences acquisition. The result is a growth-plus-deleveraging story rather than a pure defensive generics play.

Amneal carries meaningful leverage, with net debt of roughly $2.5 billion and a net-debt-to-EBITDA ratio near 3.8x, which amplifies both upside and downside and limits financial flexibility. Core generics face persistent pricing pressure, patent litigation from branded rivals, and thin margins that have compressed across the industry. Biosimilars are capital-intensive and face steep list-price erosion once competitors launch, plus shifting FDA guidance and IRA-related dynamics that complicate returns. The Kashiv acquisition adds integration and execution risk, and much of the equity value assumes the specialty and biosimilar transition keeps compounding. Any slowdown in approvals, launches, or margin gains would pressure both the growth thesis and the deleveraging path.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Amneal Pharmaceuticals, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$3.0B
• Q1 2026 net revenue: ~$723M (up ~4% YoY)
• Q1 2026 adjusted EBITDA: ~$202M (up ~19% YoY)
• 2026 revenue guidance: ~$3.05B to $3.15B
• Market cap: ~$5.4B
• Net debt: ~$2.5B (~3.8x EBITDA)

Amneal reaffirmed 2026 guidance of roughly $3.05 to $3.15 billion in net revenue and about $740 to $770 million in adjusted EBITDA. The stock has traded on a relatively rich earnings multiple versus generics peers, reflecting expectations for its specialty and biosimilar growth. Enterprise value of roughly $7.7 billion sits well above market cap because of the substantial debt load.

There are three common ways to get AMRX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so AMRX sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where AMRX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

AMRX is a leveraged generics maker trying to remix toward higher-margin specialty and biosimilar drugs, a transition story where execution and the balance sheet matter as much as the top line.

Whether AMRX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AMRX a buy?, and where the stock could go from here in the AMRX stock forecast.

For income investors, whether AMRX pays a dividend and how the payout looks is covered in does AMRX pay a dividend?